[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
Editorial
January 2017

Rituximab in Treatment-Refractory Myasthenia Gravis

Author Affiliations
  • 1Department of Neurology, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo
JAMA Neurol. 2017;74(1):21-23. doi:10.1001/jamaneurol.2016.4367

Myasthenia gravis (MG) is the prototypic autoimmune neurologic disease caused by an antibody to the nicotinic acetylcholine receptor (AChR) in most patients. Less often, an antibody to muscle-specific tyrosine kinase (MuSK) and a growing number of other postsynaptic proteins are believed to be responsible. Although MG is usually treated effectively with acetylcholinesterase inhibitors, corticosteroids, or so-called corticosteroid-sparing agents, such as azathioprine and mycophenolate mofetil, 10% to 15% of patients have difficult-to-control disease, commonly referred to as treatment-refractory MG.1 Maintenance treatment options in refractory MG are somewhat limited but may include long-term use of high-dose corticosteroids, intravenous immunoglobulin (IVIg), or plasma exchange (PE). In the past decade, rituximab, a chimeric murine-human monoclonal antibody against CD20+ B cells, has been the centerpiece of an increasing number of reports claiming success in managing refractory MG.

×